RADAR – A randomised, multi-centre, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with haemodynamically relevant atherosclerotic renal artery stenosis by Schwarzwälder, Uwe et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Trials
Open Access Study protocol
RADAR – A randomised, multi-centre, prospective study 
comparing best medical treatment versus best medical treatment 
plus renal artery stenting in patients with haemodynamically 
relevant atherosclerotic renal artery stenosis
Uwe Schwarzwälder, Michael Hauk and Thomas Zeller*
Address: Department Angiology, Herz-Zentrum Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany
Email: Uwe Schwarzwälder - uwe.schwarzwaelder@herzzentrum.de; Michael Hauk - michael.hauk@herzzentrum.de; 
Thomas Zeller* - thomas.zeller@herzzentrum.de
* Corresponding author    
Abstract
Background: Prospective, international, multi-centre, randomised (1:1) trial to evaluate the clinical impact of
percutaneous transluminal renal artery stenting (PTRAS) on the impaired renal function measured by the
estimated glomerular filtration rate (eGFR) in patients with haemodynamically significant atherosclerotic renal
artery stenosis.
Methods: Patients will be randomised to receive either PTRAS using the Dynamic Renal Stent system plus best
medical treatment or best medical treatment. Renal stenting will be performed under angiographic imaging. For
patients randomised to best medical treatment the degree of stenosis measured by renal duplex sonography
(RDS) will be confirmed by MR angio or multi-slice CT where possible. Best medical treatment will be initiated
at randomisation or post procedure (for PTRAS arm only), and adjusted as needed at all visits. Best medical
treatment is defined as optimal drug therapy for control of the major risk factors (blood pressure ≤ 125/80
mmHg, LDL cholesterol ≤ 100 mg/dL, HbA1c ≤ 6.5%). Data recordings include serum creatinine values, eGFR,
brain natriuretic peptide, patients' medical history and concomitant medication, clinical events, quality of life
questionnaire (SF-12v2™), 24 hour ambulatory blood pressure measurement, renal artery duplex ultrasound and
echocardiography. Follow-up intervals are at 2, 6, 12 and 36 months following randomisation.
The primary endpoint is the difference between treatments in change of eGFR over 12 months. Major secondary
endpoints are technical success, change of renal function based on the eGFR slope change between pre-treatment
and post-treatment (i.e. improvement, stabilisation, failure), clinical events overall such as renal or cardiac death,
stroke, myocardial infarction, hospitalisation for congestive heart failure, progressive renal insufficiency (i.e. need
for dialysis), need of target vessel revascularisation or target lesion revascularisation, change in average systolic
and diastolic blood pressure, change in left ventricular mass index calculated from echocardiography, difference
in the size of kidney (pole to pole length) measured by renal duplex sonography, total number, drug name, drug
class, daily dose, regimen and Defined Daily Dose (DDD), of anti-hypertensive drugs, and change in New York
Heart Association (NYHA) classification. Approximately 30 centres in Europe and South America will enrol
patients. Duration of enrolment is expected to be 12 months resulting in study duration of 48 months.
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Background
Renal artery stenosis (RAS) usually refers to a disease of
the large extra-renal arterial vessels and most frequently is
caused by atherosclerotic obstructions. Arterial hyperten-
sion, progressive renal failure and flash pulmonary
oedema are clinical manifestations of RAS requiring inter-
vention and treatment and may be resolved by revascular-
isation therapy. In the past, RAS was under recognised,
under diagnosed and under treated. With improved non-
invasive imaging techniques such as magnetic resonance
imaging angiography, computed tomography angiogra-
phy and high resolution renal duplex sonography, the
diagnosis is currently more frequently established.
Atherosclerosis accounts for approximately 90% of cases
with RAS and most commonly involves the origin and the
proximal third of the main renal artery. In fact, ostial RAS
can be considered as a combined disease of the aorta and
the renal artery, rather than an isolated problem of the
renal arteries. The prevalence of atherosclerotic RAS
increases with age, male gender, traditional cardiovascular
risk factors (hypertension, diabetes, smoking, disease, in
particular aorto-iliac occlusive disease) [1]. However, the
true prevalence of atherosclerotic RAS in unselected
patients is unknown. In hypertensive patients, a signifi-
cant RAS is observed in below 5% [2], whereas a preva-
lence of up to 12% has been reported in patients with
coronary artery disease undergoing cardiac catheterisation
[3] and up to 40% in patients with peripheral artery dis-
ease (PAD). Undoubtedly, atherosclerotic RAS is a pro-
gressive disease [4], as more than half of the patients
exhibit an increasing degree of stenosis within five years
after diagnosis [5], and one out of five patients with a crit-
ical stenosis suffers renal atrophy and renal failure during
this period [1].
RAS may be treated conservatively by so called best medi-
cal treatment, surgically, or by endovascular interventions
using balloon angioplasty and stenting. Applying
endovascular therapy, there is general agreement that
ostial lesions should be stented as it improves primary
patency rates and reduces the burden of reintervention [6-
11].
The indications for endovascular treatment are a matter of
ongoing debates. Curing hypertension by means of angi-
oplasty rarely occurs, although the number of antihyper-
tensive medication usually can be reduced after successful
treatment. Currently three randomised controlled trials
(RCT) on the effects of balloon angioplasty compared to
medical treatment of RAS in hypertensive patients have
been published [12-15], and a systematic review re-ana-
lysed the combined data [15]. However, there is still a lack
of evidence concerning the indications for treatment in
patients with hypertension, because each of these studies
had severe limitations.
Targeting ischaemic nephropathy, according to single cen-
tre reports revascularisation could stabilise or at least slow
the decline of renal function. However, none of the
former RCT's was designed to analyse this clinical end-
point. The largest of these 3 trials – DRASTIC [12] – did
not find any advantage of angioplasty with respect to
renal function. Yet, interpretation of DRASTIC is ham-
pered by a high proportion of cross-over (48%) from best
medical therapy to intervention after 3 months of follow-
up due to insufficient blood pressure control and an out-
dated interventional technique (plain balloon angi-
oplasty). Moreover, the study included patients with
moderate diameter stenosis (50% to 70%) that are
unlikely to cause haemodynamic compromise. Neverthe-
less, in the balloon group, an increase of GFR of 15 ml/
min was documented whereas best medical therapy
resulted in a slight decline of GFR. This result was insignif-
icant as a consequence of small sample size; only 102
patients were enrolled in this trial.
Interventional treatment has been demonstrated to be
safe, durable and effective at improving hypertension,
slowing the progressive decline in renal function [12,16-
20] and in cases also improving renal function [7,20].
Nevertheless, angioplasty also bears the risk of inducing
renal deterioration. Careful patient selection remains the
most crucial point in renal interventions; however, cur-
rent data are insufficient to give final recommendations
on this issue. Even the just recently orally presented results
of the up to date largest randomised trial (ASTRAL – Angi-
oplasty and STent for Renal Artery Lesions presented by
lead investigator Philip Kalra at the annual meeting of the
American College of Cardiology ACC 2008) are hampered
by a large selection bias of the enrolled patients.
This study (RADAR) is designed to compare the best med-
ical treatment versus the best medical treatment plus renal
artery stenting with the Dynamic Renal stent (BIO-
TRONIK, Bülach, Switzerland) in patients with haemody-
namically significant atherosclerotic renal artery stenosis.
The key inclusion criterion is the proof of significance of
RAS by duplex ultrasound in terms of significantly
reduced intra-renal resistance index and extended acceler-
ation time at the affected side. Both parameters correlate
closely with an angiographic diameter reduction of at
least 70%. This selection criterion should exclude patients
without haemodynamically relevant RAS from study
entry.
Methods
Study design
RADAR is designed as randomised, multi-centre, prospec-
tive study. Patients with haemodynamically relevant
atherosclerotic RAS matching the inclusion and passing
all exclusion criteria will be randomised to receive best
medical treatment or best medical treatment plus renalTrials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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artery stenting. Best medical treatment is defined as opti-
mal drug therapy for control of hypertension (blood pres-
sure ≤ 125/80 mmHg), of hypercholesterolemia (LDL ≤
100 mg/dL), and of diabetes (HbA1c ≤ 6.5%).
The objective of this study is to evaluate the clinical
impact of percutaneous transluminal renal artery stenting
(PTRAS) on the impaired renal function measured by the
estimated Glomerular Filtration Rate (eGFR) in patients
with haemodynamically relevant atherosclerotic RAS. Fur-
thermore the effect of PTRAS on renal function, hyperten-
sion and quality of life in comparison to medical
treatment will be evaluated. Safety and efficacy of both
treatments are further endpoints of this study. Figure 1
shows the study profile.
Serum Creatinine (SCr) values and eGFR will be assessed
from patient's medical files after obtaining informed con-
sent, and a blood sample for determination of the base-
line value will be obtained. At time of randomisation the
patient's medical history and concomitant medication,
clinical events and quality of life will be recorded. A 24
hour ambulatory blood pressure measurement will be
obtained. Renal stenting will be performed under angiog-
raphy imaging. For patients randomised to best medical
treatment the degree of stenosis measured by renal duplex
sonography will be confirmed by MR angiogram or multi-
slice CT where possible. Best medical treatment will be
initiated at randomisation or post procedurally (for
PTRAS arm only), and adjusted as needed at all visits. For
all patients renal duplex sonography will be performed at
baseline, post procedure (for PTRAS arm only), and at 6
and 12 months follow up. Clinical events will be obtained
at baseline and during all visits including a telephone fol-
low up 3 years after randomisation. Twenty four hour
ambulatory blood pressure measurement and blood sam-
pling for eGFR determination will be done at baseline,
post procedure (for PTRAS arm only), and after 2, 6 and
12 months. Adverse events and concomitant medication
will be recorded up to 12 months after randomisation. At
baseline, 6 and 12 months patients' quality of life will be
assessed using a validated general health quality instru-
ment (SF-12v2™). For further assessments see flow chart
and table of events. Patients randomised to the 'no revas-
cularisation'-group and presenting with a severe increase
in serum creatinine concentration indicating the need of
renal replacement therapy, or recurrent flash pulmonary
oedema despite existing multidrug therapy (5 drugs), may
receive a Dynamic Renal stent.
Only patients who have given written informed consent
in accordance with the applicable regulations, the Decla-
ration of Helsinki, GCP and ISO 14155 will be enrolled in
the trial. The trial is conducted in compliance with the
Declaration of Helsinki. The trial was approved by the
central ethics commission "Ethik-Komission der Albert-
Ludwigs-Universität Freiburg", Freiburg, Germany
Endpoints
Primary Endpoint: The primary endpoint is the difference
between treatments in change of eGFR over 12 months.
Secondary Endpoints: Secondary endpoints are defined as:
￿ Change in eGFR at 2, 6 and 12 months.
Study profile Figure 1
Study profile.Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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￿ Difference between treatments in change of eGFR over 2
and 6 months.
￿ Difference in eGFR slope between pre-treatment and
post treatment time points at 2, 6 and 12 months.
￿ Change of renal function based on the eGFR slope
change between pre-treatment and post-treatment at 2, 6
and 12 months (i.e. improvement, stabilisation, failure).
￿ Ratio of average Resistance Index (RI) at baseline, 6 and
12 months. Intra-renal Resistance Index is defined and
calculated by the following formula: Intra-renal RI = (Peak
Systolic Velocity-End Diastolic Velocity)/Peak Systolic
Velocity.
￿ Degree of restenosis at 6 and 12 months.
￿ Clinical events overall: renal or cardiac death, stroke,
myocardial infarction, hospitalisation for congestive heart
failure, progressive renal insufficiency (i.e. need for dialy-
sis), need for permanent renal replacement therapy, and
need of target vessel revascularisation (TVR) or target
lesion revascularisation (TLR) at 2, 6 and 12 months, and
3 years.
￿ Clinical events renal: renal death according to ICD 10,
progressive renal insufficiency (i.e. need for dialysis),
need for permanent renal replacement therapy, and need
of TVR or TLR at 2, 6 and 12 months, and 3 years.
￿ MACCE: cardiac death, stroke, myocardial infarction,
hospitalisation for congestive heart failure at 2, 6 and 12
months, and 3 years.
￿ Technical success, defined as successful access and
deployment of the device with appropriate lesion cover-
age, stent positioning and patency determined by angiog-
raphy.
￿ Acute procedural success, defined as residual percent
diameter stenosis <30% by quantitative computerised
angiography.
￿ Procedural success, defined as successful lesion crossing
and stent positioning without the occurrence of a serious
adverse event up to the moment the introducer sheath is
removed,
￿ Average systolic and diastolic blood pressure (i.e. ambu-
latory 24 h-BP) at baseline, post procedure, 2, 6 and 12
months.
￿ Change in average systolic and diastolic blood pressure
(i.e. ambulatory 24 h-blood pressure monitoring) at 2, 6
and 12 months.
￿ Left ventricular mass index (LVMI) calculated from
echocardiography or cardiac magnet resonance imaging at
baseline and 12 months. The LVMI [g/m2] is defined as
left ventricular mass divided by body surface area [m2].
Left ventricular mass is calculated by using the method
described by Devereux and Reichek [21], or as supplied by
the manufacturer of the echo device.
￿ Difference in the size of kidney (pole to pole length) at
baseline, 6 and 12 months measured by renal duplex
sonography.
￿ Total number, drug name, drug class, daily dose, regi-
men and Defined Daily Dose (DDD), of anti-hypertensive
drugs at baseline, 2, 6 and 12 months.
￿ Change in anti-hypertensive therapy at 2, 6 and 12
months.
￿ Classification of heart failure according to the New York
Heart Association (NYHA) at baseline, 2, 6 and 12
months.
￿ Change in NYHA classification of heart failure at 2, 6
and 12 months.
￿ Quality of life at baseline, 6 and 12 months (i.e. SF-
12v2™).
￿ Change in quality of life at 6 and 12 months.
￿ Patient survival
￿ Laboratory parameters at baseline, 2, 6 and 12 months
(blood), or baseline and 12 months (urine).
￿ Adverse events.
Patient population
Three hundred patients will be included to yield at least
250 patients with valid primary endpoint. Patients will be
enrolled in approximately 30 centres in Europe and South
America. Patient recruitment should be finished within 1
year following the initiation of the last study centre. Study
duration would be 4 years.
Selection of participants for this study will be documented
on the screening log. The patients being eligible for this
study must meet ALL of the following inclusion and
NONE of the exclusion criteria.
Inclusion Criteria
1. Age ≥ 18 years,
2. Informed consent signed by patient (and/or legal
guardian),Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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3. Haemodynamically relevant de novo unilateral or bilat-
eral RAS (≥ 70%). In case of unilateral disease, haemody-
namically relevant RAS is defined by an intra-renal
Resistance Index difference dRI > 0.05 (RI values compar-
ison between the two individual kidneys). The lower RI
value indicates the kidney with the stenosed artery. In
presence of bilateral symmetric disease, RAS ≥ 70% is
defined by an acceleration time more than 0.07 sec.
4. Estimated GFR > 10 ml/min calculated using the abbre-
viated Modification of Diet in Renal Disease (MDRD)
Study equation,
5. Patients presenting mild, moderate or severe hyperten-
sion (defined according to the WHO guidelines) and/or
renal dysfunction,
6. Target lesion must be completely coverable by one
study stent (total target lesion length estimated to be less
than 19 mm),
7. Target lesion accessible to direct stenting or, after pre-
dilation, is likely to sufficiently benefit from stenting (at
the discretion of the investigator),
8. Renal reference vessel diameter (RVD) of ≥ 4.0 mm and
< 7.0 mm based on visual estimation,
9. Willingness to comply with all the specified follow-up
evaluations.
Exclusion Criteria
Target indication and treatment:
1. Estimated GFR ≤ 10 ml/min,
2. Renal atrophy or kidney length < 7 cm (referring to kid-
ney with target lesion),
3. Patient not eligible for PTRA,
4. Patient not eligible for stenting,
5. Target lesion occlusion,
6. Target lesion and/or target vessel proximal to the target
lesion is severely calcified,
7. Treatment of branch lesion required,
8. Fresh thrombus or embolic lesion,
Medical history
9. Need for embolic protection in previous or planned
PTRAS,
10. Clotting disorders,
11. INR < 2.5 in patients using warfarin treatment,
12. Patient presents fibromuscular dysplasia,
13. Prior revascularisation of target lesion,
14. History of target vessel revascularisation within the
last 6 months,
15. Angiographic restenosis of any segment of the target
vessel that has undergone prior percutaneous interven-
tion,
16. Any thrombolytic therapy procedure within 72 hours
prior to planned study procedure
17. Active peptic ulcer or gastro-intestinal bleeding,
18. Active inflammation of the kidney interfering with
diagnosis and treatment of RAS (e.g. glomerulonephritis,
aortitis, vasculitis),
19. Radiation damage of the kidney,
20. Renal disease associated with aortic aneurysm i.e.
diameter of the aorta > 40 mm,
21. Chronic renal replacement therapy,
22. Life expectancy < 1 year,
23. Co-morbid conditions limiting participation and fol-
low-up,
Others
24. Patient currently participating in another trial possibly
influencing the safety of the patient and/or the outcomes
of the study,
25. Pregnancy/Planned pregnancy/Childbearing potential
without sufficient measures to prevent pregnancy as
judged by the investigator,
26. Known allergy to contrast medium that cannot be ade-
quately controlled with pre-medication,
27. Known intolerance against acetylic-salicylic acid
(ASA), heparin, clopidogrel and ticlopidin, cobalt-chro-
mium,
28. Metformin intake not stopped at least 3 days before
the intervention.Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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Sample Size Calculation, Statistics, and Calculations
Sample Size Calculation
The primary endpoint is the difference between treat-
ments in change of eGFR over 12 month. For this end-
point the intention-to-treat population (ITT) will be taken
for primary analysis.
Definitions:
￿ Controls expectation value μC, variance σC 
2 and group
size nC = Medication
￿ Treatment expectation value μT, variance σT 
2 and group
size nT = Medication and Stent
A two-sided test will be performed.
￿ Null hypothesis: H0: μT = μC
￿ Alternative hypothesis: HA: μT ≅. μC (↔.μT < μC or μT >
μC)
￿ Minimum difference: Δ = μT - μC
￿ Variances: σT 
2 and σC 
2
￿ Level of significance: α
￿ Statistical power: 1 - β
￿ Sample size: N = nT + nC
Calculations
The sample size (N) has been calculated using the meth-
ods of Bock J, 1998 [22] and Chow
SC, 2003 [23], N = nT + nC. 4 (u1.α/2 + u1.β)2 (σ/Δ)2 for
σC 2 = σT 2 = σ2
The probability for incorrect rejection of H0 for a two-
sided test (α/2 = 0.025) is u1-0.025 = 1.9600.
The probability for correct rejection of H0 (1-β = 80%) is
u0.8 = 0.8416.
Based on published data [24], the estimated GFR differ-
ence between baseline and 12 month follow-up in
patients with unilateral RAS>70% is 4.35 ml/min. Moreo-
ver, from the DRASTIC study [25] considering the patient
population with bilateral stenosis the estimated GFR dif-
ference at 12 months was 10.0 ± 16 ml/min. Furthermore,
in a usual patient population the proportion of patients
with bilateral RAS is 15% to 20%. This leads to a calcu-
lated increase of estimated ΔGFR for a mixed cohort of
patients with unilateral and/or bilateral RAS of approxi-
mately: ΔeGFR = 0.2*10+0.8*4.35 ≈ 5.5 ml/min μT = 5.5
ml/min.
In addition, for the medication group, we can assume an
eGFR difference or decrease of
μC = -1.0 ml/min at 12 months follow up.
The relevance level is assumed to be 20% of the difference
between the therapy and medication or control group.
Therefore, the sample size can be calculated as shown in
Table 1.
Considering a drop-out rate of approximately 20%, and a
PTRAS rate of 20% of patients being initially randomised
to BMT group, a total of 300 patients will be enrolled, 150
patients per group. A study patient that has been with-
drawn from the study will not be replaced. It is intended
to include between 6 and 24 patients per centre.
Secondary endpoints
Improvement or stabilisation of renal function
The improvement or stabilisation of the renal function
will be determined by change in eGFR at baseline/before
start of treatment and 12 months after start of therapy.
The following definitions will be used to assess the out-
come on the renal function for comparison of the stent
plus best medical therapy and the best medical therapy
alone group [26]:
￿ Improvement: Increase of the absolute value of the eGFR
after treatment by equal or more than 10% compared to
the baseline value
Table 1: Calculation of sample size
Expectation value Relev. Variance1/2 Sig. level Statistical Sample
Therapy Ref. Min. diff. level Therapy Ref. k = 1-sided power size
mueT mueC Delta delta sigmaT sigmaC nT/nC alpha = 0.05 1-beta N = nT+ nC
5.5 -1.0 6.5 2.0 14.0 14.0 1.50 1 0.80 250Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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￿ Stabilisation: Absolute value of the eGFR within ± 10%
of the baseline value
￿ Failure: Decrease of the absolute value of the eGFR after
treatment by equal or more than 10% compared to the
baseline value.
GFR can be estimated by including serum creatinine with
other demographic measurements in a prediction equation.
These equations are valid only if the renal function is in a
steady state, which can be defined by a constant serum creat-
inine in a given time interval. The eGFR will be calculated
according to the following Modification of Diet in Renal Dis-
ease (MDRD) Study Prediction equation: eGFR (ml/min/
1.73 m2) = 170 × [serum creatinine, mg/dL]-0.999 × [age in
years]-0.176 × [0.762 if female] × [1.180 if black] × [serum urea
nitrogen, mg/dL]-0.17 × [serum albumin, g/dL]+0.318
Renal resistance index
Intra-renal Resistance Index (RI) will be calculated by the
following formula: Intra-renal RI = (Peak Systolic Veloc-
ity-End Diastolic Velocity)/Peak Systolic Velocity
An intra-renal resistance index difference ΔRI > 0.05 is
defined as haemodynamically relevant.
(≥ 70% diameter stenosis) in case of unilateral lesions,
with the lower value on the side of stenosis.
Restenosis rate
Diagnosis of restenosis will be based on a colour-coded
renal duplex sonography. A haemodynamically relevant
unilateral restenosis (≥ 70%) is defined by a ΔRI more
than 0.05. For bilateral lesions, haemodynamically rele-
vant restenosis is defined by an acceleration time of more
than 0.07 sec.
In case of haemodynamically relevant restenosis patients
will be treated according to hospital practice.
Clinical events
Clinical events will be analysed for:
￿ Overall combined events (i.e. renal or cardiac death,
stroke, myocardial infarction, hospitalisation for conges-
tive heart failure, progressive renal insufficiency (i.e. need
for dialysis), need for permanent renal replacement ther-
apy, and need of TVR or TLR),
￿ renal clinical events (i.e.,. renal death defined as patient
death classified according to the International Classification
of Disease, Tenth _Revision (ICD-10) codes N00-N07, N17-
N19, and N25-N27, progressive renal insufficiency (i.e.
need for dialysis), need for permanent renal replacement
therapy, and need of TVR or TLR),
￿ MACCE (i.e. cardiac death, stroke, myocardial infarc-
tion, hospitalisation for congestive heart failure),
￿ individual events.
Determination of technical success
Technical success defined as successful access and deploy-
ment of the device with appropriate lesion coverage, stent
positioning and patency determined by angiography at
the time of deployment [27].
Procedural success
Acute procedural success defined as residual percent
diameter stenosis <30% by quantitative computerised
angiography [27]. Percent diameter stenosis is calculated
as residual target lesion lumen divided by diameter refer-
ence segment. Procedural success defined as successful
lesion crossing and stent positioning without the occur-
rence of a serious adverse events up to the moment the
introducer sheath is removed [27].
Evaluation of blood pressure
Blood pressure will be monitored in every patient
throughout the study as part of the basic medical care. In
addition to that 24 hour ambulatory blood pressure will
be recorded at randomisation, post procedure, at 2, 6 and
12 months (except post procedure for conservative
group).
After completion of the study, average 24 h-blood pres-
sure will be analysed and categorised according to the fol-
lowing definitions [34]:
￿ Cure: Diastolic blood pressure < 80 mm Hg and systolic
blood pressure < 125 mmHg, off anti-hypertensive medi-
cations.
￿ Improvement: Diastolic blood pressure < 80 mmHg
and/or systolic blood pressure < 125 mmHg on the same
or reduced number of medications, or a reduction in
diastolic blood pressure by at least 15 mmHg on the same
or reduced number of medications.
￿ Failure: no change or inability to meet above criteria for
cure or improvement.
￿ Benefit: cure or improvement.
Left ventricular mass index
Left ventricular mass index (LVMI) will be assessed by
echocardiography or MR angiography at baseline and 12
months. LVMI (g/m2) is defined as the left ventricular
mass divided by the body surface [m2]. Parameters for
assessing myocardial muscle mass will be acquired by an
experienced examiner according to the Guidelines of the
American Society of Echocardiography. Therefore, myo-Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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cardial muscle mass is calculated by using the method
described by Devereux and Reichek, or as supplied by the
manufacturer of the ECHO device. It has to be ensured
that the same method is used in an individual patient.
Kidney size
The size of the kidney supplied by the renal artery that
determined the patient's eligibility for the study will be
measured by renal duplex sonography at baseline and
after 6 and 12 months.
Evaluation of anti-hypertensive medication
All medication of the patients will be recorded in the CRFs
and any changes in the medication must be recorded. Per
patient antihypertensive medication will be analysed
according to total number of anti-hypertensive medica-
tions, drug name, drug class, daily dose and regimen.
Change in medical treatment will be compared with
regard to anti-hypertensive medication using the classifi-
cation of WHO daily defined doses (DDD). Total amount
of anti-hypertensive medication recorded at different time
points will be calculated according to the following for-
mula:
Dose per day/DDD for this drug
Anti-hypertensive medication for each patient at baseline,
2, 6 and 12 months will be compared to the medication
taken before randomisation.
Classification of heart failure
Heart failure will be classified according to the classifica-
tion of the New York Heart Association at baseline, 2, 6
and 12 months.
Quality of Life assessment
During the study the quality of life will be assessed at
baseline, 6 and 12 months using a validated question-
naire [28] (SF-12v2™) established to measure the impact
of disease on the patients' quality of life. It has been used
extensively as a screening tool, and is frequently used as
part of longer, condition-specific surveys. Questionnaires
will be supplied in the validated version of local lan-
guage(s) of each participating country.
Patient survival
Patient survival will be calculated after the last follow-up
has been completed as percentage of patients still alive
and followed-up compared to treated/randomised
patients.
Evaluation of safety
The safety of the Dynamic Renal stent will be analysed by
adverse events and device related adverse events.
Statistical Analyses
All patients will be analysed on an intent-to-treat basis.
Data analysis will be performed on all patients who meet
the eligibility requirements of this study using descriptive
methods. Discrete variables will be presented as counts
and percentage of the total. Continuous variables will be
presented as mean ± standard deviation. In case of relative
likelihoods the exact one-sided confidence interval of
95% will be calculated.
For the confirmatory analysis of relative likelihoods a
binominal test will be performed. For the confirmatory
analysis of metric data a t-Test will be performed. If a Kol-
mogorov-Smirnov-Test shows the data are not normally
distributed, a non-parametric Wilcoxon-Test or in case of
an inter-individual comparison of 2 datasets a Mann-
Whitney-U-Test will be performed.
It is intended to perform the following sub analyses:
- Analysis by treated lesion,
- Analysis including time points after receipt of the
Dynamic Renal stent during the study from patients ini-
tially randomised to the no revascularisation group.
Other subgroup analyses will be specified in the statistical
analysis plan.
Definition of Clinical Events
Adverse Event Reporting: An Adverse Event is any untoward
medical occurrence in a clinical investigation patient,
which does not necessarily have a causal relationship with
this treatment. An adverse event (AE) can therefore be any
unfavourable and unintended sign (including an abnor-
mal laboratory finding), symptom, or disease temporally
associated with the use of a medical (investigational)
product, whether or not related to the medical (investiga-
tional) product. Significant device failure may constitute
an adverse event if an undesirable experience occurs.
Adverse events information will be collected throughout
the study in the Case Report Forms (CRF). Adverse events
will be recorded on the CRF by the Investigator or a per-
son authorised by the investigator. Event, date of onset,
severity, duration, and relationship to device or prescribed
drug regimen (see 5.7) will be recorded in the CRF. Any
adverse events will be monitored until they are adequately
resolved or reach a stable state.
Adverse Device Effect
An adverse device effect is any untoward and unintended
response to a medical device. This includes any event
resulting from insufficiencies or inadequacies in the
instructions for use or the deployment of the device. AlsoTrials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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user errors that result in an untoward and unintended
response are included. Adverse device effects information
will be documented in the CRF as adverse events related
to the device.
Serious Adverse Event
Serious adverse events are adverse events that
a) led to death,
b) led to a serious deterioration in the health of the sub-
ject that
1) resulted in a life-threatening illness or injury,
2) resulted in a permanent impairment of a body structure
or a body function,
3) required in-patient hospitalisation or prolongation of
existing hospitalisation,
4) resulted in medical or surgical intervention to prevent
permanent impairment to
body structure or a body function.
c) led to foetal distress, foetal death or a congenital abnor-
mality or birth defect.
The Investigator must judge on whether each event meets
the definition of a "serious" adverse event. All serious
adverse events and deaths must be reported by fax to BIO-
TRONIK AG within 24 hours after the investigator learns
of the event using the SAE report forms. These are pro-
vided to the investigator together with the CRFs.
Serious Adverse Device Effect
Adverse device effect that has resulted in any of the conse-
quences characteristic of a serious adverse event or that
might have led to any of these consequences if suitable
action had not been taken or intervention had not been
made or if circumstances had been less opportune. Seri-
ous adverse device effects (SADE) must be reported by fax
to BIOTRONIK AG within 24 hours after the investigator
learns of the event using the SAE report forms. These are
provided to the investigator together with the CRFs.
Regulatory Reporting
Investigators are responsible for reporting SAEs and
SADEs to their reviewing Independent Ethic Committee
(IEC)/Institutional Review Board (IRB) according to the
local applicable regulations.
Criteria of Judgment on Relationship to Treatment
All adverse and serious adverse events have to be judged
by the investigator for their relation to the study treatment
by help of the following criteria: timely relation of the
event to the procedure, known risks of the device and
intervention, concomitant diseases, concomitant meas-
ures and medication, other possible explanations, as
applicable. Causality to the treatment will be judged using
the following categories: not related, possibly related,
probably related, related. No other category applies. Doc-
umentation about judgment and causality assessment has
to be available for review and be provided upon request.
Study device
The BIOTRONIK Dynamic Renal stent system incorpo-
rates the latest technical developments of approved state-
of-the art renal stent systems. The safety and performance
of these reference devices was demonstrated in clinical
studies which together included more than 260 proce-
dures. Dynamic Renal is equivalent to the reference stent
systems (Palmaz Blue from Cordis Corporation a Johnson
& Johnson company and Herculink Elite from Abbott Vas-
cular Corporation) due to its very similar design, materi-
als and technical characteristics. Although the clinical
behaviour of a stent system can not be entirely predicted
from its technical characteristics or its similarity with
established stent systems, it is justified to expect that the
Dynamic Renal stent system will be equivalent to the mar-
keted predecessor and reference devices during clinical
use.
The Dynamic Renal stent is a tubular, balloon-expandable
stent sculpted by laser from a single tube of L-605 cobalt-
chromium (CoCr) alloy. The stent consists of circular seg-
ments at each end followed by a transition zone and struts
arranged in a double helix in the middle. Each loop of the
helices is connected to the next loop by 2–3 (alternating)
longitudinal struts. This design is broadly similar to that
of the approved Dynamic stent system [29]. The stent sur-
face is fully coated with a layer of amorphous hydrogen-
rich silicon carbide (a-SiC:H). This material has semi-con-
ducting properties that efficiently prevent the electron
transfer from fibrinogen to the metal surface in vitro.
Thereby the conversion from fibrinogen to fibrin and it's
deposition at the stent surface is reduced [30]. Addition-
ally, a-SiC:H-coated stents exhibit a lower adhesion and
activation of blood platelets and leucocytes [31]. Finally,
the release of potentially allergenic ions from a silicon car-
bide coated stent is substantially reduced in comparison
to an uncoated metal stent. This coating is used on all
BIOTRONIK coronary and peripheral stents produced so
far and was evaluated in a number of clinical studies
[6,32-36]. Full information can be deduced from the
applicable instructions for use.
The stent delivery system is based on a rapid-exchange
balloon catheter. The stent is securely crimped on a polya-
mide balloon situated at the distal tip of the catheter
between two radiopaque markers made of a Platinum-Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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Iridium alloy. The proximal shaft of the delivery system
consists of a polyamide tube (PA12) that incorporates a
stiffening wire made of stainless steel (AISI 301) to
improve its pushability. It has a single Luer port for con-
necting an inflation/deflation device to inflate/deflate the
balloon. The distal section of the catheter comprises the
inflation/deflation (balloon) lumen and the 15 cm long
guide wire lumen which starts at the catheter tip and ends
at the guide wire exit. It accepts guide wires of 0.014"
diameter. The stent delivery system is compatible with
guiding catheters with a minimal inner diameter of 0.070
inch (1.78 mm, 6F sheath compatible) or introducer
sheaths of 4 to 5 F.
Device sizes
The Dynamic Renal stent system is available in 16 differ-
ent variants. The stent is available in lengths of 12 and 19
mm. It is pre-mounted on a delivery system which has
nominal balloon diameters of 4.5, 5.0, 6.0 and 7.0 mm
and usable lengths of 80 cm and 140 cm respectively that
allow a femoral or brachial/radial access route.
Study Committees
Data and Safety Monitoring Board (DSMB)/Clinical Events 
Committee (CEC)
In this study, the DSMB/CEC is composed of five mem-
bers (four physicians with sufficient experience in the tar-
geted indication, and one biostatistician), who are
independent of the conduct of the trial.
Based on the safety data, the DSMB/CEC may recommend
to modify or stop the trial. The DSMB/CEC will discuss
and classify all clinical events for later analysis. At the
onset of the trial, the DSMB/CEC established explicit rules
outlining the minimum amount of data required, and the
algorithm followed in order to classify a clinical event.
BIOTRONIK will compile clinical event packets when the
necessary data are available from the investigative sites.
They will provide this information to the DSMB/CEC. The
DSMB/CEC will meet based on event rate accrual to
review and adjudicate all clinical events for which the
required minimum data is available. The Committees will
also review and rule on all deaths that occur throughout
the trial.
Coordinating and Co-Coordinating Investigators
Thomas Zeller, MD, Department Angiology, Herz-Zen-
trum Bad Krozingen, Südring 15, 79189 Bad Krozingen,
Germany,
Marco V. Wainstein, MD PhD, Hospital de Clinicas de
Porto Alegre, Serviço de Cardiologia
Sala 2059, Rua Ramiro Barcelos, 2350, Porto Alegre, RS
90035-003, Brazil
Sponsor of the study
BIOTRONIK AG, Ackerstrasse 6, 8180 Bülach, Switzerland
Discussion
The RADAR study is the first randomised controlled trial
on the impact of RAS compared to best medical therapy
based on a strict physiological definition of the main
inclusion criterion, the degree of stenosis. The lumen
reduction of the lesion must result in a measurable reduc-
tion of kidney perfusion distal to the stenosis expressed by
a significant reduction of the resistance index of the
affected kidney. This reduction of the resistance index
nicely correlates to an at least 70% diameter reduction by
angiography [37,38]. With this strict inclusion criterion it
is intended to randomise only patients in whom restora-
tion of normal kidney perfusion should have an impact
on kidney function and with this by modulating the renal
hypoperfusion triggered humoral disorders also an
impact of secondarily affected organs such as the heart
and the brain.
All former comparative studies on RAS were more liberal
with their inclusion criteria accepting even moderate
degrees of RAS, e.g. DRASTIC included about one third of
patients having a degree of angiographic diameter stenosis
less than 70% [12]. Even the recently at the Annual Meet-
ing of the American College of Cardiology (Philip Kalra)
presented so far largest study including more than 800
patients, the ASTRL trial, enrolled 25% of the patients
with RAS less than 70% (range 20–100%) diameter sten-
osis. Due to the inclusion of patients without haemody-
namically relevant RAS and the small sample sizes
(DRASTIC 102 patients), all currently published studies
failed in proving a significant benefit of renal artery inter-
vention on blood pressure control and renal function [12-
14]. Noteworthy GFR in the DRASTIC study increased by
15 ml/min in the balloon angioplasty group whereas it
slightly decreased by 1 ml/min in the control arm. How-
ever, the study was not powered adequately to show a sig-
nificant difference. The sample size calculation for the
present study was based on a recently published pilot
study (PRECISON [39]) for the trial and the so far
reported controlled trial data. Enrolling in total 300
patients in a 1:1 randomised fashion we expect a signifi-
cant difference in the primary study endpoint, the differ-
ence between treatments in change of eGFR over 12
months.
Renal function is one of the most powerful predictors of
survival [40]. Another one is left ventricular hypertrophy
[41]; the analysis of the course of left ventricular mass
index is also included as a secondary endpoint because
the reducing the activation of the renin-angiotensin-
aldosterone-system by RAS revascularisation should lead
to a regression of left ventricular hypertrophy [41]. Affect-Trials 2009, 10:60 http://www.trialsjournal.com/content/10/1/60
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ing these major endpoints, renal function and left ven-
tricular hypertrophy, RAS stenting should also impact the
composite clinical endpoint of patient survival, hospitali-
sation and end-stage renal failure after 3 years.
Provided a timely initiation of all study sites it is expected
to finish patient enrolment within 1 year so that the anal-
ysis of the primary endpoint should be available in 2011.
Conclusion
Based on the strict physiological definition based on
reduction of the resistance index, including only patients
with haemodynamically relevant RAS and on enrolling in
total 300 patients in a 1:1 randomised fashion the
expected outcome of the study is a significant difference in
the primary study endpoint, the difference between treat-
ments in change of eGFR over 12 months.
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